drugset
drugset / Trial / NCT06390098

Positron Emission Tomography Study in Healthy Subjects to Determine the Relationship Between Plasma Concentration and Brain Target Occupancy of ASN51

NCT06390098 ↗

Phase 1 Completed 3 enrolled Asceneuron S.A. Hammersmith Medicines Research Invicro · collab
NaSequentialOpen-labelTreatment

Summary

This is a phase 1, open-label, positron emission tomography (PET) study in healthy adult participants to determine the relationship between plasma concentration and brain target occupancy of ASN51 following a single oral dose.

Timeline

Start
2021-08-09
Primary completion
2021-10-12
Completion
2021-10-12

Drugs

EvaluationDrugModalityDoseRoute
Subject ASN51 Unknown — —

Indications

No indication recorded.